Entera Bio (NASDAQ:ENTX) Shares Up 5.1% – Here’s Why

Shares of Entera Bio Ltd. (NASDAQ:ENTX) shot up 5.1% during mid-day trading on Thursday . The stock traded as high as $3.24 and last traded at $3.27. Approximately 89,894 shares changed hands during trading, a decline of 92% from the average daily volume of 1,130,988 shares. The stock had previously closed at $3.11.

Analysts Set New Price Targets

Several equities analysts recently commented on ENTX shares. Wall Street Zen upgraded Entera Bio to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Entera Bio presently has a consensus rating of “Hold” and an average target price of $9.00.

Entera Bio Price Performance

The firm’s 50 day moving average price is $2.12 and its two-hundred day moving average price is $1.57. The stock has a market cap of $559.24 million, a PE ratio of -9.23 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Analysts anticipate that Entera Bio Ltd. will post -0.34 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

A number of large investors have recently modified their holdings of the company. Superstring Capital Management LP bought a new stake in Entera Bio during the 4th quarter worth approximately $33,000. Citadel Advisors LLC grew its position in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after purchasing an additional 28,322 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after purchasing an additional 25,000 shares during the period. Jane Street Group LLC raised its position in shares of Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after buying an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares in the last quarter. 14.11% of the stock is currently owned by institutional investors.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.